Tradestie Institutional Equity Comparison Engine

EPRX vs ENTA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EPRX Overall Edge

EPRX Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) driven by superior Growth & Margin, Momentum & Technical while ENTA counters with relative strength in Valuation, Options & Structure. Fundamentally, EPRX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ENTA at 44.0x Forward P/E and -90.0% operating margin (-21.6% YoY). In options structure, EPRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ENTA sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ENTA
EPRX N/M vs ENTA 44.0x Fwd P/E
Growth & Margin Winner EPRX
Op Margin 0.0% vs -90.0% ยท YoY +0.0% vs -21.6%
Momentum & Technical Winner EPRX
1Y +18.9% vs -7.9% ยท 52W Pos 52% vs 10%
Options & Structure Winner ENTA
UNCLASSIFIED (N/A IV) vs BREAKDOWN (11th %ile IV)
EPRX NASDAQ
Eupraxia Pharmaceuticals Inc. Common Stock
Pharmaceutical Preparations
$7.54
-7.48% 1D
Market Cap $525.4M
1M Return +13.9%
1Y Return +18.93%
Forward P/E N/M
Unified AI Score
34.1 / 100 SELL
Tech 15.0 Fund 40.0 Flow 50.0 Mom 54.0
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
1M Return -2.79%
1Y Return -7.94%
Forward P/E 44.0x
Unified AI Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EPRX +18.93% ENTA -7.94% Spread: +26.87 pp (EPRX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EPRX TTM Op. Margin: 0.0% ENTA TTM Op. Margin: -90.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EPRX vs ENTA. Trailing 12-month operating profitability (EPRX 0.0% vs ENTA -90.0%) and valuation multiples (EPRX N/M vs ENTA 44.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EPRX (6) vs ENTA (4)
Institutional Metric EPRX ENTA Criterion Row Winner
Market Capitalization Scale $525.4M $326.2M Larger Scale EPRX
Trailing P/E Ratio Valuation N/M 44.0x Lower Multiple ENTA
Forward P/E Ratio Valuation N/M 44.0x Lower Multiple ENTA
Revenue Growth (YoY) Growth +0.0% -21.6% Higher Growth EPRX
Operating Margin (TTM) Profitability 0.0% -90.0% Higher Margin EPRX
Net Profit Margin Profitability 0.0% -96.9% Higher Margin EPRX
Return on Equity (ROE) Capital Efficiency -56.4% -70.1% Higher ROE EPRX
52-Week Range Position Momentum 52% ($6โ€“$9) 10% ($10โ€“$17) Stronger Trend EPRX
Beta / 30D Volatility Risk Regime 1.71ฮฒ ยท 77% Vol 0.89ฮฒ ยท 58% Vol Lower Realized Risk ENTA
Unified Institutional Score Composite Signal 34.1 / 100 (SELL) 46.2 / 100 (HOLD) Higher Composite ENTA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EPRX vs ENTA Buy Guide
EPRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EPRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ENTA BREAKDOWN
95d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live ENTA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EPRX nor ENTA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.